Health

New Lung Cancer Drug Should Help Patients Live Longer

In the District of Columbia, the Centers for Disease Control and Prevention estimates 310 new cases of lung cancer this year and 220 deaths.

Further, 40 people per 100,000 in the District get lung cancer, making it the top cause of cancer death in the nation’s capital. It’s also a leading cause of cancer deaths among African-Americans in D.C., with 7 out of 10 black men more likely to be diagnosed with lung and bronchus cancer than any other group and 8 out of 10 more likely to die from the disease than others.

In Maryland, 60.3 people per 100,000 get lung cancer, while that number increases in Baltimore City to 79.5 per 100,000, according to health experts. And those figures are just for white residents.

“Unfortunately, when it comes to African-Americans, it’s higher,” said Dr. Kashif Ali of the Maryland Oncology Hematology Center and local expert in immuno-oncology.

Approximately 67.6 African-American residents per 100,000 citizens get lung cancer, Ali said, quoting statistics. That number rises to 81.5 per 100,000 in Baltimore City.

“Genetics is part of it and so is the socio-economic status,” Ali said. “The lack of education in certain communities contributes to it as well. But, over the past couple of years the general incidence have dropped because of education and getting people more educated about the risk of smoking, the benefits of cancer screenings, going to the doctor and catching things early.”

Still, health experts need to do more in communities of color to educate them on the risks of lung cancer, Ali said.

Now, health officials have cited new developments in immuno-oncology — an innovative area of research that seeks to help the body’s own immune system fight cancer — that offers hope to patients diagnosed with lung cancer.

Recent information presented by researchers has revealed that patients with lung cancer who are treated with the drug, Opdivo — a type of medicine that uses immuno-oncology to help the body fight cancer — are now living for three years after diagnosis.

Bristol-Myers Squibb Company announced the three-year overall survival data from two pivotal randomized studies called CheckMate -017 and CheckMate -057.

Those studies evaluated Opdivo versus the chemotherapy drug Docetaxel in patients with previously treated metastatic non-small-cell lung cancer — the most common type of lung cancer.

In CheckMate -017, 16 percent of patients treated with Opdivo were alive at three years versus the 6 percent treated with Docetaxel.

In CheckMate -057, 18 percent of patients treated with Opdivo were alive at three years versus 9 percent who took Docetaxel.

“One of the things we learned over the past few years is that the immune system has the natural ability to fight cancer,” Ali said. “In general, our bodies develop cells that look like cancers on a daily basis and it’s the type of cell that’s called the T-cell that fights it off.”

In order to avoid being attacked by the immune system, healthy cells are disguised with molecules that turn T-cells off whenever they come near.

As normal cells transition into a cancerous state, some pick up the ability to coat themselves in these so-called checkpoint molecules, allowing them to put the brakes on even a robust immune system attack, according to one published report.

“If we can activate that ability of immune system to fight off cancers we can do it a lot better and with less side effects compared to other treatments we’ve had in the past which were mostly focused on chemotherapy,” Ali said.

“There are a few drugs that have come out, Opdivo being the one mentioned in the studies and the way this drug works is the way some of the immune therapy drugs work and what happens is that the cancer cells growing in your body become very smart and they figure out a way to trick the immune system by making a block so when the T-cells come and attack they become inactivated,” he said.

The blocks then prevent the immune system from killing off the cancer cells.

Opdivo removes that block from cancer cells preventing T-cells from becoming inactivated, Ali said.

“The nice thing about this drug is that it’s actually using your own immune system to fight this cancer instead of introducing toxins like chemotherapy which generally leads to a lot more side effects,” he said.

Tags
Show More

Stacy M. Brown

I’ve worked for the Daily News of Los Angeles, the L.A. Times, Gannet and the Times-Tribune and have contributed to the Pocono Record, the New York Post and the New York Times. Television news opportunities have included: NBC, MSNBC, Scarborough Country, the Abrams Report, Today, Good Morning America, NBC Nightly News, Imus in the Morning and Anderson Cooper 360. Radio programs like the Wendy Williams Experience, Tom Joyner Morning Show and the Howard Stern Show have also provided me the chance to share my views.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Back to top button

My News Matters to me - Washington Informer Donations

Be a Part of The Washington Informer Legacy

A donation of your choice empowers our journalists to continue the work to better inform, educate and empower you through technology and resources that you use.

Click Here Today to Support Black Press and be a part of the Legacy!

Subscribe today for free and be the first to have news and information delivered directly to your inbox.

Select list(s) to subscribe to


By submitting this form, you are consenting to receive marketing emails from: Washington Informer Newspaper, 3117 Martin Luther King Jr. Ave SE, Washington, DC, 20032, http://www.washingtoninformer.com. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact
Close

Adblock Detected

Please consider supporting us by disabling your ad blocker